Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Esperion ( (ESPR) ) is now available.
On November 4, 2025, Esperion Therapeutics announced the appointment of John B. Harlow, Jr. as the new Chief Commercial Officer, effective November 17, 2025. Harlow, who previously served as Chief Commercial Officer at Melinta Therapeutics, brings extensive experience in driving commercial strategies and enhancing sales and marketing performance. His appointment is expected to play a crucial role in expanding the adoption of Esperion’s cardiovascular risk reduction therapies and increasing the company’s global presence. Harlow’s leadership is anticipated to accelerate the delivery of innovative therapies to patients worldwide, furthering Esperion’s growth and market impact.
The most recent analyst rating on (ESPR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
Esperion’s overall stock score is primarily influenced by its robust earnings call performance, which highlights significant revenue growth and strategic achievements. However, the company’s financial performance is a major concern due to negative equity and ongoing profitability challenges. Technical analysis shows positive momentum, but valuation remains unattractive due to negative earnings and lack of dividends.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing new medicines for patients with cardiovascular disease, particularly those struggling with elevated low-density lipoprotein cholesterol (LDL-C). The company offers the only FDA-approved oral, once-daily, non-statin medications for such patients, supported by the CLEAR Cardiovascular Outcomes Trial.
Average Trading Volume: 6,708,234
Technical Sentiment Signal: Buy
Current Market Cap: $683.3M
See more data about ESPR stock on TipRanks’ Stock Analysis page.